MedDRA Coding Quality: How to Avoid Common Pitfalls

Similar documents
Seeing Chickens at Window Recording Adverse Events and GeneratingQuality Data. Margaret Band, Clinical Trial Manager, TCTU

Preview of New MedDRA Hierarchy for Medication Errors Coding and Retrieval Considerations

Data retrieval using the new SMQ Medication Errors

MedDRA Overview A Standardized Terminology

MedDRA Basic Concept

MedDRA Coding and Versioning

Coding with MedDRA 4/22/2015

Coding with MedDRA 3/6/2019

Other EU Activities Contributing to Harmonization of Labeling

MedDRA - International standard for coding safety information. The Golden Triangle

CTCAE & Source Documentation. Elizabeth Ness, RN, MS Director, Office of Education and Compliance Center for Cancer Research

Advanced MedDRA Coding

GDUFA: 2 ½ years later Impact & Importance

Regulatory Experience in Reviewing CV Safety for Diabetes

Coding with MedDRA. MedDRA trademark is owned by IFPMA on behalf of ICH

Coding with MedDRA. of the MedDRA Maintenance and Support Services Organization (MSSO) are overseen by an ICH MedDRA

Coding with MedDRA 3/2/2017

Overview of the MedDRA Data Retrieval and Presentation: Points to Consider Document including Standardised MedDRA Queries (SMQs)

MedDRA TERM SELECTION: POINTS TO CONSIDER

MedDRA TERM SELECTION: POINTS TO CONSIDER

MedDRA TERM SELECTION: POINTS TO CONSIDER

Disclaimer. The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be

Global Pediatric Development: We Are Making Progress. PMDA Perspective. Junko Sato, PhD PMDA

The Telemetric and Holter ECG Warehouse (THEW) Initiative

MedDRA Term Selection: Latest activities of the Points to Consider Working Group

Disclaimer. Statistical Aspects of Revision of CHMP Bioequivalence Guidelines. David Brown MHRA

Summary of Changes to. MedDRA TERM SELECTION: POINTS TO CONSIDER

9/20/2011. Impact of EU Paediatric Regulation on drug development and Marketing authorisations Industry experience

MedDRA TERM SELECTION: POINTS TO CONSIDER

MedDRA Coding/ AE Log Item 1 Refresher. ASPIRE Protocol Team Meeting February 10, 2013

Introduction to MedDRA

Web-based epro: Validation, Equivalence, and Data Quality. Brian Tiplady

Safety Data Analysis and Query Creation with MedDRA

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER

3/31/2009. Phase 0 Microdosing Studies with Renin Inhibitors. Disclaimer. Overview of Today s Presentation. J. Chris Jensen Consultant

Healthcare Professional Information & Patient Information Leaflet (PL)

Instruct patient and caregivers: Need for constant monitoring Potential complications of drug therapy

PMDA Perspectives on Oncology Panel. REIKO YANAGIHARA, Ph.D. Office of In Vitro Diagnostics PMDA

Coding with MedDRA 1

So, My FitBit is Clinical Trial Grade Right? Keith Wenzel Senior Director, Solution Incubator PAREXEL International

Coding with Confidence

Disclaimer. Dialogue with a Patient 3/18/2016

Data Analysis and Query Building with MedDRA

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER

Coding with MedDRA 1

What s New MedDRA Version March

What s New MedDRA Version March

Cardiology. Objectives. Chapter

Safety Assessment in Clinical Trials and Beyond

What Medical Writers Need to Know About MedDRA

Food can serve as a non pharmacological control in thorough cardiac safety studies

Regulatory scientific significance of Japan s ADR relief system

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER

Use of MedDRA in Special Situations

Summary of Changes to. MedDRA TERM SELECTION: POINTS TO CONSIDER

Building Higher Order Thinking Skills in Tomorrow s Health Care Professionals A Quality Enhancement Plan for the GSBS

Data Analysis and Query Building with MedDRA

What s New MedDRA Version 13.1

The Adverse Reactions and Interactions

Electrocardiographic Markers Associated with Sotalol-induced Torsades de Pointes

10/27/2011. Challenges in Anti-diabetic Global Drug Development A Shift from Surrogate to Outcome Trials. Disclaimer

Nursing Process Focus: Patients Receiving Dextran 40 (Gentran 40)

Conducting Observational studies in Latin America: Academia, Ethical Committees & Pharmaceutic Industry

Centralized Procedure

Coding with MedDRA. Course Overview

Heart Disorders. Cardiovascular Disorders (Part B-1) Module 5 -Chapter 8. Overview Heart Disorders Vascular Disorders

NHS Grampian Staff Guideline for the Management of Acute Hypokalaemia in Adults

Pharmacy Prep. Qualifying Pharmacy Review

Pre-marketing Assessment of Drug Safety

MedDRA 13.0 Review. General Remarks. Version 13.0 Changes Overview. Changes in a Nutshell. Changes Highlights. MedDRA Version Changes

EKG Competency for Agency

Bioequivalence Requirements: USA and EU

Terminologies for recording of ADR:s

SYNOPSIS. Date 15 June 2004

Implemented MedDRA Version 22.0 Complex Changes (October 2018)

What s New MedDRA Version 14.0

What s New MedDRA Version MSSO-DI March 2016

CMS Limitations Guide - Cardiovascular Services

Electrocardiography for Healthcare Professionals

MULTIPLE CHOICE. Choose the one alternative that best completes the statement or answers the question.

Elements for a Public Summary

Presenter: Steven Brust, HCS-D, HCS-H Product Manager, Home Health Coding Center

A COPD medication delivery device option: an overview of the NEOHALER

12.1 Apply Your Knowledge How long does an ambulatory monitor typically remain on a patient?

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

Focus On Signs and Symptoms

Farmakovijilans ve MedDRA Pharmacovigilance and MedDRA FARMAKOVİJİLANS ve FARMAKOVİJİLANS UYGULAMALARI EKİM Dr.

Acid Base Balance by: Susan Mberenga RN, BSN, MSN

Best practices in VeDDRA coding

CHAPTER 4 POST-MARKETING SURVEILLANCE OF DRUGS

Introductory Guide MedDRA Version 15.0

Supplement Table 1. Definitions for Causes of Death

DRUG TESTING IN PAIN MANAGEMENT AND SUBSTANCE USE DISORDER(S) TREATMENT

Introductory Guide MedDRA Version 18.1

DIA Oligonucleotide-Based Therapeutics Conference

Risk Adjustment Documentation & Coding Improvement Reference Information for 2017

Introductory Guide MedDRA Version 14.0

Evaluating Exam Review Book and Guide

HOMES AND SENIORS SERVICES. APPROVAL DATE: February 2011 REVISION DATE: January 2015; July 2018

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER

Transcription:

MedDRA Coding Quality: How to Avoid Common Pitfalls Patricia Mozzicato, MD Chief Medical Officer MedDRA MSSO Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. ( DIA ), its directors, officers, employees, volunteers, members, chapters, councils, Special Interest Area Communities or affiliates, or any organization with which the presenter is employed or affiliated. These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. Drug Information Association, Drug Information Association Inc., DIA and DIA logo are registered trademarks. All other trademarks are the property of their respective owners. 2 1

Data Quality in Clinical Development Highly regulated environment with strong emphasis on safety surveillance and data quality Applies to clinical trials and post-marketing arena Increasing harmonization of safety reporting regulations globally 3 What is Meant by Good Quality Data? Complete Accurate Diagnosis supported by appropriate investigations Causality assessment for adverse events 4 2

Coding of Clinical Trial Data Most data entered on Case Report Forms are coded in some form Facilitates storage, retrieval, analysis, and presentation of data Some coding is performed by investigators at point of data entry For example, numeric codes for severity of adverse event: 1= mild, 2= moderate, etc. Other coding of text data is performed by sponsor company after data collection Accuracy of initial coding determines accuracy of analysis 5 Quality of Input = Quality of Output IN OUT 6 3

MedDRA Definition MedDRA is a clinically-validated international medical terminology used by regulatory authorities and the regulated biopharmaceutical industry. The terminology is used through the entire regulatory process, from pre-marketing to postmarketing, and for data entry, retrieval, evaluation, and presentation. 7 Key Features of MedDRA Structure facilitates data analysis and reporting and electronic communication Large terminology with >69,000 terms at lowest level allows greater specificity Approx. 19,000 Preferred Terms (PTs), each representing a unique medical concept Used for coding adverse events, signs and symptoms, procedures, investigations, indications, medical and social histories, medication errors and product quality issues 8 4

MedDRA Structure SOC = Cardiac disorders HLGT = Cardiac arrhythmias HLT = Rate and rhythm disorders NEC LLT Arrhythmia NOS LLT Arrhythmia PT = Arrhythmia LLT (Non-current) Other specified cardiac dysrhythmias LLT Dysrhythmias 9 MedDRA Structure (cont) 10 5

Problems With Coding Data Appropriate coding requires clear initial data What is clear to investigator at point of data entry may be unclear to sponsor at point of data coding Sponsor must only code reported verbatim term; not permitted to interpret or draw information from other sources Example: Ambiguous information Congestion (nasal, liver, sinus, pulmonary?) Cramp (muscle, menstrual, abdominal?) Pain (pain where?) 11 Problems With Coding Data (cont) Example: Ambiguous abbreviations MI (myocardial infarction or mitral incompetence?) GU pain (gastric ulcer pain or genito-urinary pain?) Decreased BS (breath sounds, bowel sounds or blood sugar?) Exercise caution with abbreviations that could be misinterpreted ECG, COPD, HIV are examples of standard abbreviations 12 6

Problems With Coding Data (cont) Example: Vague information Patient felt fuzzy, weird, experienced every adverse event Try to use accepted medical terminology Example: Non-specific information Left wrist edema (coded as LLT Peripheral edema) More specific - Injection site edema left wrist (coded as LLT Injection site edema) 13 Problems With Coding Data (cont) Death, hospitalization, and disability are outcomes and are not usually considered to be adverse events Provide details of underlying event, if known Examples: Death due to myocardial infarction (Coded as LLT Myocardial infarction with death captured as outcome) Hospitalization due to congestive heart failure (Coded as Congestive heart failure with hospitalization captured as outcome) 14 7

Problems With Coding Data (cont) Example: Ambiguous laboratory data Glucose of 40 (Source of specimen - blood, urine, CSF? What units?) Would have to code as LLT Glucose abnormal if additional clarification is not obtained Example: Conflicting laboratory data Hyperkalemia with serum potassium of 1.6 meq/l Would have to code as LLT Serum potassium abnormal If using numeric values, provide units and reference range. Be specific about specimen source and diagnostic result/clinical diagnosis. 15 Problems With Coding Data (cont) Example: Combination terms Diarrhea, nausea and vomiting Try to avoid combination terms these will have to be split into three individual terms Diarrhea Nausea Vomiting 16 8

Reporting a Specific Diagnosis Where possible, report most important medical event or specific diagnosis rather than individual signs and symptoms Can provide provisional diagnosis, e.g., possible, presumed, rule out Accuracy is important in preventing dilution of safety signals or generating false signals SIGNS and SYMPTOMS DIAGNOSIS Chest pain, dyspnea, diaphoresis, ECG changes Myocardial infarction 17 Benefits of Quality Data Accuracy in diagnosis is important for detection and evaluation of safety signals Accurate and timely information on issues that affect conduct of clinical trial and affect patient safety Improved communication among sponsors, investigators, and regulatory agencies about medicinal products Ensures accuracy of information about product including investigators brochures and prescribing information Benefits medical professionals and patients 18 9

How to Achieve Quality in MedDRA Coding Quality assurance steps Coding conventions Synonym lists 19 Quality Assurance Steps Coding QA reports Human oversight of automated coding results E.g., Adrenal insufficiency secondary to chronic traditional medication intake autoencoded as LLT Secondary adrenal insufficiency Secondary adrenal insufficiency is based on lack of ACTH or CRH Better term is LLT Adrenal insufficiency 20 10

Quality Assurance Steps (cont) Qualification of coder/review staff Errors in MedDRA should be addressed by submission of Change Requests to MSSO; no ad hoc structural alterations to MedDRA 21 MedDRA Coding Conventions Differences in medical aptitude of coders Consistency concerns (many more choices to manually code terms in MedDRA compared to older terminologies) Even with an autoencoder, may still need manual coding Should be consistent with ICH s MedDRA Term Selection: Points to Consider document 22 11

Synonym Lists Can be derived from existing term lists or directly from verbatims For recurring, but unusual, verbatims onetime assignment to a MedDRA term Enforces consistency by limiting choices once MedDRA term is assigned Increases likelihood of autoencoding hit Natural outgrowth of a legacy data conversion Maintenance required 23 In Summary Quality of initial data and quality of coding ultimately affect quality of analysis Be aware of potential pitfalls in coding with MedDRA There are ways to address quality issues such as coding conventions, etc. 24 12

Quality Data IN OUT 25 Thank You 13